Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

Clinical trial NCT04911517 · UNKNOWN

Trial details

NCT number: NCT04911517
Sponsor: Beijing Friendship Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Neoplasms

Start date: 2021-06-01
Primary completion: 2022-12-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.